Case could also be made that if juul was worth 10x what they paid they may not even be looking at LXRP tech.
Insiders got a major boost in compensation which is going to backfire on investors because these capital raises keep on diluting us. So with that extra $$ they are making maybe add shares in open market?
2020 was supposed to be start of pharma division. We are almost finished with 2 months of the year what has happened with that?
Management has been stating revenues are going to increase substantially. I mean this can very well be achieved because it’s subjective. $0 one quarter and $10 the next I guess that was increased substantially 10x. But I’m looking for these statements to actually come to fruition.
News 
Market Data 
Discover 
